These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1152 related items for PubMed ID: 31300482

  • 1. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W, Liang G, Xie X, Jiang W, Tan L, Sanders AJ, Liu Z, Ling Y, Zhong W, Tian Z, Lin W, Gong C.
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [Abstract] [Full Text] [Related]

  • 2. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
    Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, Burwinkel B.
    Clin Cancer Res; 2012 Nov 01; 18(21):5972-82. PubMed ID: 22952344
    [Abstract] [Full Text] [Related]

  • 3. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X, Ma F, Li C, Wu S, Hu S, Huang J, Sun X, Wang J, Luo Y, Cai R, Fan Y, Li Q, Chen S, Zhang P, Li Q, Xu B.
    Cancer Commun (Lond); 2019 Jan 03; 39(1):1. PubMed ID: 30606259
    [Abstract] [Full Text] [Related]

  • 4. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment.
    Fischer C, Turchinovich A, Feisst M, Riedel F, Haßdenteufel K, Scharli P, Hartkopf AD, Brucker SY, Michel L, Burwinkel B, Schneeweiss A, Wallwiener M, Deutsch TM.
    Int J Mol Sci; 2022 Aug 23; 23(17):. PubMed ID: 36076930
    [Abstract] [Full Text] [Related]

  • 5. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.
    Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S.
    Ann Oncol; 2015 Mar 23; 26(3):510-6. PubMed ID: 25471333
    [Abstract] [Full Text] [Related]

  • 6. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jörgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K, Rydén L.
    Breast Cancer Res; 2018 Jun 08; 20(1):48. PubMed ID: 29884204
    [Abstract] [Full Text] [Related]

  • 7. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schönfisch B, Taran FA, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A.
    BMC Cancer; 2015 May 14; 15():403. PubMed ID: 25972110
    [Abstract] [Full Text] [Related]

  • 8. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
    Alunni-Fabbroni M, Majunke L, Trapp EK, Tzschaschel M, Mahner S, Fasching PA, Fehm T, Schneeweiss A, Beck T, Lorenz R, Friedl TWP, Janni W, Rack B, SUCCESS Study Group.
    BMC Cancer; 2018 Feb 06; 18(1):141. PubMed ID: 29409452
    [Abstract] [Full Text] [Related]

  • 9. The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study.
    Yang L, Lv Z, Xia W, Zhang W, Xin Y, Yuan H, Chen Y, Hu X, Lv Y, Xu Q, Weng X, Ni C.
    Clin Transl Oncol; 2018 Jul 06; 20(7):912-921. PubMed ID: 29243075
    [Abstract] [Full Text] [Related]

  • 10. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients.
    Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramírez-Moreno R, van Deurzen CH, Smid M, Yu JX, Jiang J, Wang Y, Gratama JW, Sleijfer S, Foekens JA, Martens JW.
    Clin Cancer Res; 2011 Jun 01; 17(11):3600-18. PubMed ID: 21505063
    [Abstract] [Full Text] [Related]

  • 11. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H, Masuda N, Yamamoto D, Sagara Y, Sato N, Yamamoto Y, Saito M, Fujita T, Oura S, Watanabe J, Tsukabe M, Horiguchi K, Hattori S, Matsuura Y, Kuroi K.
    Breast Cancer Res Treat; 2017 Apr 01; 162(3):501-510. PubMed ID: 28181129
    [Abstract] [Full Text] [Related]

  • 12. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.
    Cancer; 2008 Nov 01; 113(9):2422-30. PubMed ID: 18785255
    [Abstract] [Full Text] [Related]

  • 13. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Wang C, Mu Z, Chervoneva I, Austin L, Ye Z, Rossi G, Palazzo JP, Sun C, Abu-Khalaf M, Myers RE, Zhu Z, Ba Y, Li B, Hou L, Cristofanilli M, Yang H.
    Breast Cancer Res Treat; 2017 Jan 01; 161(1):83-94. PubMed ID: 27771841
    [Abstract] [Full Text] [Related]

  • 14. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
    Ušiaková Z, Mikulová V, Pintérová D, Brychta M, Valchář J, Kubecová M, Tesařová P, Bobek V, Kološtová K.
    In Vivo; 2014 Jan 01; 28(4):605-14. PubMed ID: 24982230
    [Abstract] [Full Text] [Related]

  • 15. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H, Fasching PA, Gumbrecht W, Jud S, Rauh C, Matzas M, Paulicka P, Friedrich K, Lux MP, Volz B, Gass P, Häberle L, Meier-Stiegen F, Hartkopf A, Neubauer H, Almstedt K, Beckmann MW, Fehm TN, Ruebner M.
    BMC Cancer; 2018 Feb 20; 18(1):204. PubMed ID: 29463222
    [Abstract] [Full Text] [Related]

  • 16. Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.
    Markou A, Zavridou M, Sourvinou I, Yousef G, Kounelis S, Malamos N, Georgoulias V, Lianidou E.
    Clin Chem; 2016 Jul 20; 62(7):1002-11. PubMed ID: 27197674
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M, Fujii K, Akizuki M, Imai T, Fukutomi T, Kobayashi K.
    Breast Cancer; 2016 Jan 20; 23(1):120-127. PubMed ID: 24906662
    [Abstract] [Full Text] [Related]

  • 18. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
    Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, Wagner J, Kimmig R, Kasimir-Bauer S.
    Oncotarget; 2016 Jul 05; 7(27):41677-41690. PubMed ID: 27223437
    [Abstract] [Full Text] [Related]

  • 19. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z, Wang C, Ye Z, Rossi G, Sun C, Li L, Zhu Z, Yang H, Cristofanilli M.
    Breast Cancer Res Treat; 2017 Oct 05; 165(3):733-741. PubMed ID: 28687903
    [Abstract] [Full Text] [Related]

  • 20. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
    Müller V, Banys-Paluchowski M, Friedl TWP, Fasching PA, Schneeweiss A, Hartkopf A, Wallwiener D, Rack B, Meier-Stiegen F, Huober J, Rübner M, Hoffmann O, Müller L, Janni W, Wimberger P, Jäger B, Pantel K, Riethdorf S, Harbeck N, Fehm T, DETECT study group.
    ESMO Open; 2021 Dec 05; 6(6):100299. PubMed ID: 34839105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.